Do tirzepatide and semaglutide curb compulsive habits?
No label we checked for tirzepatide (Mounjaro, Zepbound) or semaglutide (Ozempic, Wegovy), including the US, EU, UK, Canadian and Australian labels, lists a use for addiction or compulsive habits. Small trials found semaglutide cut some drinking measures and smoking craving, but not cigarettes a day. Tirzepatide addiction trials have no results yet. We found no gambling, shopping or skin-picking trials.
Are these medicines approved for addiction or impulse control?
No. None of the US labels for Mounjaro, Zepbound, Ozempic or Wegovy lists addiction, compulsive habits or impulse control among its uses.1,2,3,4
The US labels approve them for type 2 diabetes or weight management, and for some linked heart, kidney, liver or sleep problems.1,2,3,4 Each label sets a weekly dose schedule. Zepbound starts at 2.5 mg once a week and rises in 2.5 mg steps, every 4 weeks or more, to at most 15 mg.2 Wegovy injection starts at 0.25 mg once a week.4
What do trials show for alcohol and smoking?
Three small trials found semaglutide cut some drinking measures in people with alcohol use disorder, but a smoking trial missed its main goals.5,6,7,8
A 9-week US trial in 48 adults cut alcohol drunk in a lab session, its main measure, and also cut drinks per drinking day and craving, but not the number of drinking days.5 A Danish trial gave 108 adults with obesity talk therapy plus semaglutide 2.4 mg weekly or a dummy injection (placebo) for 26 weeks. Heavy-drinking days fell 41 percentage points, against 26 on placebo.6 Stomach side effects were more common on semaglutide, mostly mild to moderate.6 An 8-week trial of semaglutide tablets in 50 adults did not cut craving in the lab, its main measure, but cut craving in daily life and heavy-drinking days.7
In a 9-week trial of 24 adults who smoked daily, semaglutide cut craving. It did not cut cigarettes per day, one of its main measures.8 Tirzepatide is being tested for alcohol, opioid, methamphetamine, cannabis and smoking problems. None of the 16 studies we found had posted results by 16 Nov 2026.9
Is there evidence for gambling, shopping, skin picking or OCD?
We found no published trial of tirzepatide or semaglutide for gambling, compulsive shopping, skin picking, hair pulling or obsessive-compulsive disorder (OCD).10,11
A search of the Europe PMC research database on 16 Nov 2026 found reviews and single-patient case reports, but no controlled trials.11 ClinicalTrials.gov lists one semaglutide trial for hair pulling (trichotillomania). It had not started recruiting.10 We also found no trial that measured new compulsions, such as extra shopping, on these medicines.11
Can these medicines change mood or behaviour?
A 2026 FDA review of 91 trials found no higher risk of depression, anxiety, irritability or suicidal thoughts with GLP‑1 medicines than with placebo.12
The trials covered 107,910 people. The FDA then asked the makers of Wegovy, Zepbound and Saxenda (liraglutide, a related medicine) to remove a suicidal thoughts warning.12 A pooled look at 4,056 people in three tirzepatide weight trials found no rise in depression against placebo.13 The Canadian and Australian labels still ask doctors to watch for unusual changes in mood or behaviour.14,15,16,17
What do people on GLP‑1 medicines report about compulsive habits?
From public patient forums: 55 Reddit threads in r/Zepbound, r/Semaglutide, r/Mounjaro, r/mounjarouk, r/Ozempic and r/WegovyWeightLoss, read from October 2025 to October 2026. Personal reports, not medical evidence.
What people describe
- Matches the trials, in part Many say their wish to drink dropped. In small trials, semaglutide cut some drinking measures but not others.5,6,7
- Matches a small trial, in part Many say they smoked or vaped less, while several noticed no change. In one small trial, semaglutide cut craving but not cigarettes per day.8
- Not studied Many describe fewer impulse buys. Many others describe new urges to shop, collect or take up hobbies. We found no study of shopping on these medicines.
- Not studied Several say nail biting, skin picking or hair pulling eased. Several others saw no change, or got worse. We found no published study, and one hair-pulling trial has not started.10
Advice people share
- Matches the FDA, in part Several say to tell your doctor about drinking, drug use or changes in mood. The FDA advises telling a health professional about new or worsening depression or unusual changes in mood or behaviour.12
- Not studied Several set spending limits, delete shopping apps or leave items in the basket before buying. We found no study of these steps on GLP‑1 medicines.
- Label says otherwise Several describe custom doses, “microdosing” or stretched gaps between doses to curb cravings. The US Zepbound and Wegovy labels give set once-weekly doses and list no addiction use.2,4
In your country
No label we opened lists an addiction use. Canada and Australia still ask doctors to watch for unusual changes in mood or behaviour, while the US, EU and UK labels do not.2,4,18,19,20,21
Australia
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.
Label: The Australian Mounjaro and Wegovy Product Information ask doctors to monitor for new or worse depression, suicidal thoughts and any unusual changes in mood or behaviour.16,17
Emergency number: 000
GLP-1 side effects: Ozempic and Mounjaro risks explained (Australia)
Canada
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.
Label: The Canadian Zepbound and Wegovy monographs ask doctors to monitor for unusual changes in mood or behaviour.14,15 The Zepbound and Wegovy monographs say to avoid them after a suicide attempt or with active suicidal thoughts.14,15
Emergency number: 911
GLP-1 side effects: Ozempic, Wegovy and Zepbound risks (Canada)
France
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).
Label: The answer above applies.
Emergency number: 15 or 112
Germany
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.
Label: The answer above applies.
Emergency number: 112
India
Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).
Label: We had no Indian label to open, so this page relies on the US and EU labels cited above.
Emergency number: 112
GLP-1 side effects: Ozempic and Mounjaro risks explained (India)
Saudi Arabia
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.
Label: We had no Saudi label to open, so this page relies on the US and EU labels cited above.
Emergency number: 997 or 911
United Arab Emirates
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.
Label: We had no UAE label to open, so this page relies on the US and EU labels cited above.
Emergency number: 998 for an ambulance, or 999
United Kingdom
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.
Label: The answer above applies.
Emergency number: 999
GLP-1 side effects: Ozempic and Mounjaro risks explained (UK)
United States
Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).
Label: The answer above applies.
Emergency number: 911
Contact your prescriber or a doctor right away if you have thoughts of harming yourself, new or worsening depression, unusual changes in mood or behaviour, or mental health changes that worry you.12,14
Read the full picture
Related questions
Sources
- Eli Lilly. Mounjaro (tirzepatide): US prescribing information (DailyMed), section 1. dailymed.nlm.nih.gov
- Eli Lilly. Zepbound (tirzepatide): US prescribing information (DailyMed), sections 1 and 2. dailymed.nlm.nih.gov
- Novo Nordisk. Ozempic (semaglutide): US prescribing information (DailyMed), section 1. dailymed.nlm.nih.gov
- Novo Nordisk. Wegovy (semaglutide): US prescribing information (DailyMed), sections 1 and 2. dailymed.nlm.nih.gov
- Hendershot CS et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 2025;82(4):395–405. Abstract read. DOI · PMID 39937469
- Klausen MK et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet 2026;407:1687–1698. Abstract read. DOI · PMID 42070571
- Schacht JP, Sakai JT, Raymond K, Shelton R. Oral semaglutide for alcohol use disorder: a randomized clinical trial. Am J Psychiatry 2026;183(9):636–645. Abstract read. DOI · PMID 42522065
- Hendershot CS et al. Once-weekly semaglutide in adults with daily cigarette use: a randomized clinical trial. JAMA Netw Open 2026;9(5):e2614898. Abstract read. DOI · PMID 42189538
- ClinicalTrials.gov. Searches for intervention “tirzepatide” with alcohol (7 studies) and with opioid, stimulant, methamphetamine, cannabis, nicotine, tobacco, smoking or gambling (9 studies); none with posted results, checked 16 Nov 2026. Examples: NCT06994338 (alcohol), NCT06651177 (opioid), NCT07602699 (smoking).
- ClinicalTrials.gov. Search for semaglutide or tirzepatide with gambling, compulsive buying, trichotillomania, skin picking or obsessive-compulsive disorder (1 study, checked 16 Nov 2026): Semaglutide (Wegovy) Treatment for Trichotillomania, not yet recruiting. NCT07282769
- Europe PMC. Search for semaglutide or tirzepatide with gambling, compulsive buying, skin picking, trichotillomania, nail biting or obsessive-compulsive disorder (168 records, first 40 screened; no trial of these behaviours), checked 16 Nov 2026. europepmc.org
- US Food and Drug Administration. FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. Drug Safety Communication, 13 January 2026. fda.gov
- Wadden TA et al. Psychiatric safety of tirzepatide in people with obesity and no known major psychopathology: a post hoc analysis of SURMOUNT. Obesity 2026;34(3):565–578. Abstract read. DOI · PMID 41537305
- Eli Lilly Canada. Zepbound (tirzepatide) Product Monograph, Health Canada. PDF
- Novo Nordisk Canada. Wegovy (semaglutide injection) Product Monograph, Health Canada. PDF
- Eli Lilly Australia. Mounjaro (tirzepatide) Australian Product Information. PDF
- Novo Nordisk Australia. Wegovy (semaglutide) Australian Product Information. PDF
- European Medicines Agency. Mounjaro: EU product information, sections 4.1, 4.4 and 4.8. PDF
- European Medicines Agency. Wegovy: EU product information, sections 4.1, 4.4 and 4.8. PDF
- Mounjaro KwikPen: UK summary of product characteristics (emc), sections 4.1, 4.4 and 4.8. medicines.org.uk
- Wegovy 2.4 mg FlexTouch: UK summary of product characteristics (emc), sections 4.1, 4.4 and 4.8. medicines.org.uk
- NHS (UK). Help for suicidal thoughts. nhs.uk
Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write